$4.48 Million NIH Grant for Osteoporosis Research Received by Hebrew SeniorLife, a Teaching Affiliate of Beth Israel Deaconess Medical Center and the Headquarters of the Harvard Medical School Multi-Campus Fellowship in Geriatric Medicine.

Juvent's Dynamic Motion Therapy([R]) Selected for Clinical Study to evaluate the Effect on the Improvement of Bone Mineral Density in Elderly Persons with Low Bone Density.

SOMERSET, N.J. -- Juvent, Inc., a leading developer of non-invasive, therapeutic medical devices utilizing Dynamic Motion Therapy([R]) (DMT) technology, announced today that the National Institutes of Health has awarded a grant of approximately $4.48 million to Hebrew SeniorLife, a teaching affiliate of Beth Israel Deaconess Medical Center and the headquarters of the Harvard Medical School Multi-Campus Fellowship in Geriatric Medicine, to fund a clinical study to evaluate the effect of low magnitude mechanical stimulation in improving bone mineral density in elderly individuals with low bone density using Juvent's DMT technology. Douglas P. Kiel, M.D., Associate Professor of Medicine, Harvard Medical School, and Director Medical Research, Institute for Aging Research, Hebrew SeniorLife, will serve as the study's Principal Investigator, heading a collaboration of internationally known experts in osteoporosis in older persons.

The 2 year, double-blind, placebo-controlled randomized trial with evaluate daily 10 minute treatments with DMT technology as an anabolic bone stimulus in 200 elderly (65 years and older) women and men with body mass indexes of less than 27 kg/m2 and low T-scores (from -1 to -2.0) at the hip.

The primary aim of this study will be to understand the potential for the differential effects of DMT technology on trabecular and cortical bone of the proximal femur and spine. Secondary aims will be (1) to determine the effect of the therapy on biochemical indices of remodeling and bone specific markers of formation and resorption, and (2) to explore whether absolute compliance during the 2 year trial is associated with the absolute and percentage change in volumetric trabecular bone mineral density of the proximal femur and spine among all participants randomized to the active treatment arm.

Osteoporosis, a disease characterized by compromised bone strength predisposing to an increased rate of fracture, is one of the most common age-related conditions. Fractures resulting from low bone density severely compromise the quality of life of those who suffer from this disease, while the dollar cost of acute annual health care for osteoporosis treatment surpasses $15 billion in the United States alone, and is predicted to exceed $250 billion over the next 50 years.

Juvent, Inc. is a medical device development company that has commercialized a patented Dynamic Motion Therapy technology. Based on several years of pre-clinical and pilot clinical studies, Juvent believes the DMT technology, utilizing low-level mechanical signals to prevent bone loss as well as rebuild lost bone will become the preferred therapy for control and reversal of osteoporosis and other diseases involving bone loss. For more information, visit http://www.juvent.com.

Hebrew SeniorLife (HSL) is a 100+ year-old organization committed to maximizing the quality of life of seniors through an integrated network of housing, health care, research, and teaching programs, serving more than 3,500 seniors annually in the Greater Boston area. HSL is a teaching affiliate of Beth Israel Deaconess Medical Center and the headquarters of the Harvard Medical School Multi-Campus Fellowship in Geriatric Medicine.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Juvent, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Juvent, Inc.'s business.

Dynamic Motion Therapy [R] is a registered trademark of Juvent, Inc.